Inovio Wins $80.4M Judgment Against VGXI and GeneOne, But Collection Is Uncertain
INO sits 81% above its 52-week low of $0.563.
Summary
Inovio won an $80.4M judgment in Pennsylvania state court against VGXI and GeneOne — $61.75M in compensatory damages plus $18.67M in fees and costs — and the court also ruled against the defendants' counterclaims. The case dates to June 2020, when Inovio alleged the defendants breached a supply agreement by refusing technology-transfer obligations needed for scalable DNA plasmid manufacturing. The catch: Inovio itself warns the defendants' financial condition will likely impair its ability to collect some or all of the award, so this is a legal win, not cash in hand. For a company with a going-concern warning and cash runway only into late Q1 2027, any recovery would be meaningful, but the judgment faces post-trial motions and appeal risk. The bigger near-term item remains the FDA decision on INO-3107, due October 30, 2026.
At the time of this announcement, INO was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104.4M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.